{"id":3902,"date":"2019-10-22T11:21:24","date_gmt":"2019-10-22T09:21:24","guid":{"rendered":"https:\/\/digidem-bayern.de\/?p=3902"},"modified":"2019-11-25T09:27:18","modified_gmt":"2019-11-25T08:27:18","slug":"biogen-plant-us-zulassungsantrag-fuer-aducanumab","status":"publish","type":"post","link":"https:\/\/digidem-bayern.de\/en\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\/","title":{"rendered":"\u00dcberraschende Wende: Biogen plant US-Zulassungsantrag f\u00fcr Alzheimer-Mittel"},"content":{"rendered":"

Neue Hoffnung f\u00fcr Alzheimer-Patienten? Erst im Fr\u00fchjahr stoppte der US-Biotechkonzern Biogen zwei gro\u00dfe Studien mit dem Alzheimer-Mittel Aducanumab, der Wirkstoff schien gescheitert. Doch nun gibt es eine Kehrtwende, der Konzern setzt erneut auf Aducanumab und plant sogar die US-Zulassung. <\/h4>\n\n\n\n

Mittlerweile seien mehr\nDaten verf\u00fcgbar, eine neue Analyse habe ein positives Ergebnis f\u00fcr eine der\nbeiden Studie ergeben, teilte Biogen zusammen mit seinem japanischen Entwicklungspartner\nEisai mit.<\/p>\n\n\n\n

\"Tabletten\"<\/figure><\/div>\n\n\n\n

Patienten, die Aducanumab erhielten, zeigten laut Biogen Vorteile in Bezug auf Kognition, Ged\u00e4chtnis, Orientierung und Sprache. \u201eDie Patienten zeigten auch Verbesserungen bei Aktivit\u00e4ten des t\u00e4glichen Lebens, einschlie\u00dflich der Durchf\u00fchrung pers\u00f6nlicher Finanzen, bei Haushaltsaufgaben wie Putzen, Einkaufen und Waschen sowie beim selbstst\u00e4ndigen Verlassen des Hauses\u201c, hei\u00dft es in der Pressemitteilung des Konzerns. <\/p>\n\n\n\n

Den US-Zulassungsantrag\nwill der Konzern Anfang 2020 einreichen. <\/p>\n\n\n\n

Bislang gibt\nes keine wirksame Therapie f\u00fcr die Alzheimer-Erkrankung. Gegenw\u00e4rtige\nMedikamente k\u00f6nnen lediglich die Symptome lindern. Weltweit leiden nahezu 50\nMillionen Menschen an einer Demenz, in Deutschland sind es ca. 1,7 Millionen.\nAlzheimer ist die h\u00e4ufigste Form der Erkrankung.<\/p>\n\n\n\n

Die Pressemitteilung von Biogen lesen Sie hier:<\/em><\/p>\n\n\n\n

https:\/\/www.biogen.de\/de_DE\/news-insights\/germanyaffiliatenews\/22-10-2019-news.html<\/a><\/p>","protected":false},"excerpt":{"rendered":"

Neue Hoffnung f\u00fcr Alzheimer-Patienten? Erst im Fr\u00fchjahr stoppte der US-Biotechkonzern Biogen zwei gro\u00dfe Studien mit dem Alzheimer-Mittel Aducanumab, der Wirkstoff schien gescheitert. Doch nun gibt es eine Kehrtwende, der Konzern setzt erneut auf Aducanumab und plant sogar die US-Zulassung. Mittlerweile seien mehr Daten verf\u00fcgbar, eine neue Analyse habe ein positives …<\/p>","protected":false},"author":11,"featured_media":3906,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"qubely_global_settings":"","qubely_interactions":"","_uag_custom_page_level_css":"","footnotes":""},"categories":[5],"tags":[],"class_list":["post-3902","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-wissenschaft-forschung"],"qubely_featured_image_url":{"full":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",1600,1067,false],"landscape":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-1200x750.jpg",1200,750,true],"portraits":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-540x320.jpg",540,320,true],"thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-80x80.jpg",80,80,true],"medium":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-300x200.jpg",300,200,true],"medium_large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-768x512.jpg",768,512,true],"large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-1030x687.jpg",1030,687,true],"1536x1536":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",1536,1024,false],"2048x2048":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",1600,1067,false],"trp-custom-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",18,12,false],"qubely_landscape":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-1200x750.jpg",1200,750,true],"qubely_portrait":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-540x320.jpg",540,320,true],"qubely_thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-140x100.jpg",140,100,true],"post-thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-495x330.jpg",495,330,true],"kahuna-featured":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-495x350.jpg",495,350,true],"kahuna-featured-lp":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-690x350.jpg",520,264,true],"kahuna-featured-half":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-800x350.jpg",800,350,true],"kahuna-featured-third":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-512x350.jpg",512,350,true],"kahuna-lpbox-1":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-460x350.jpg",394,300,true],"kahuna-lpbox-2":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-460x350.jpg",460,350,true],"demand-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",36,24,false],"dddkt-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",36,24,false],"ddiqc-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",36,24,false],"ddtl-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",36,24,false],"mailpoet_newsletter_max":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-1320x880.jpg",1320,880,true],"kahuna-lpbox-3":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-460x350.jpg",460,350,true],"kahuna-featured-square":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-512x512.jpg",512,512,true],"kahuna-featured-square-large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-1024x1024.jpg",1024,1024,true]},"qubely_author":{"display_name":"Michael Zeiler","author_link":"https:\/\/digidem-bayern.de\/en\/author\/michael-zeiler\/"},"qubely_comment":0,"qubely_category":"Wissenschaft & Forschung<\/a>","qubely_excerpt":"Neue Hoffnung f\u00fcr Alzheimer-Patienten? Erst im Fr\u00fchjahr stoppte der US-Biotechkonzern Biogen zwei gro\u00dfe Studien mit dem Alzheimer-Mittel Aducanumab, der Wirkstoff schien gescheitert. Doch nun gibt es eine Kehrtwende, der Konzern setzt erneut auf Aducanumab und plant sogar die US-Zulassung. Mittlerweile seien mehr Daten verf\u00fcgbar, eine neue Analyse habe ein positives …","featured_image_urls_v2":{"full":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",1600,1067,false],"thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-80x80.jpg",80,80,true],"medium":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-300x200.jpg",300,200,true],"medium_large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-768x512.jpg",768,512,true],"large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-1030x687.jpg",1030,687,true],"1536x1536":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",1536,1024,false],"2048x2048":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",1600,1067,false],"trp-custom-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",18,12,false],"qubely_landscape":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-1200x750.jpg",1200,750,true],"qubely_portrait":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-540x320.jpg",540,320,true],"qubely_thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-140x100.jpg",140,100,true],"post-thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-495x330.jpg",495,330,true],"kahuna-featured":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-495x350.jpg",495,350,true],"kahuna-featured-lp":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-690x350.jpg",520,264,true],"kahuna-featured-half":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-800x350.jpg",800,350,true],"kahuna-featured-third":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-512x350.jpg",512,350,true],"kahuna-lpbox-1":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-460x350.jpg",394,300,true],"kahuna-lpbox-2":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-460x350.jpg",460,350,true],"demand-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",36,24,false],"dddkt-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",36,24,false],"ddiqc-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",36,24,false],"ddtl-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",36,24,false],"mailpoet_newsletter_max":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-1320x880.jpg",1320,880,true],"kahuna-lpbox-3":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-460x350.jpg",460,350,true],"kahuna-featured-square":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-512x512.jpg",512,512,true],"kahuna-featured-square-large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-1024x1024.jpg",1024,1024,true]},"post_excerpt_stackable_v2":"

Neue Hoffnung f\u00fcr Alzheimer-Patienten? Erst im Fr\u00fchjahr stoppte der US-Biotechkonzern Biogen zwei gro\u00dfe Studien mit dem Alzheimer-Mittel Aducanumab, der Wirkstoff schien gescheitert. Doch nun gibt es eine Kehrtwende, der Konzern setzt erneut auf Aducanumab und plant sogar die US-Zulassung. Mittlerweile seien mehr Daten verf\u00fcgbar, eine neue Analyse habe ein positives Ergebnis f\u00fcr eine der beiden Studie ergeben, teilte Biogen zusammen mit seinem japanischen Entwicklungspartner Eisai mit. Patienten, die Aducanumab erhielten, zeigten laut Biogen Vorteile in Bezug auf Kognition, Ged\u00e4chtnis, Orientierung und Sprache. \u201eDie Patienten zeigten auch Verbesserungen bei Aktivit\u00e4ten des t\u00e4glichen Lebens, einschlie\u00dflich der Durchf\u00fchrung pers\u00f6nlicher Finanzen, bei Haushaltsaufgaben wie…<\/p>\n","category_list_v2":"Wissenschaft & Forschung<\/a>","author_info_v2":{"name":"Michael Zeiler","url":"https:\/\/digidem-bayern.de\/en\/author\/michael-zeiler\/"},"comments_num_v2":"0 comments","yoast_head":"\n\u00dcberraschende Wende: Biogen plant US-Zulassungsantrag f\u00fcr Alzheimer-Mittel - digiDEM Bayern<\/title>\n<meta name=\"description\" content=\"Iim Fr\u00fchjahr stoppte der US-Biotechkonzern Biogen zwei gro\u00dfe Studien mit dem Alzheimer-Mittel Aducanumab. Doch nun setzt der Konzern erneut auf auf den Wirkstoff und plant sogar die US-Zulassung.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/digidem-bayern.de\/en\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00dcberraschende Wende: Biogen plant US-Zulassungsantrag f\u00fcr Alzheimer-Mittel - digiDEM Bayern\" \/>\n<meta property=\"og:description\" content=\"Iim Fr\u00fchjahr stoppte der US-Biotechkonzern Biogen zwei gro\u00dfe Studien mit dem Alzheimer-Mittel Aducanumab. Doch nun setzt der Konzern erneut auf auf den Wirkstoff und plant sogar die US-Zulassung.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/digidem-bayern.de\/en\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\/\" \/>\n<meta property=\"og:site_name\" content=\"digiDEM Bayern\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/digiDEMBayern\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-22T09:21:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-11-25T08:27:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"1067\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Michael Zeiler\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Michael Zeiler\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\\\/\"},\"author\":{\"name\":\"Michael Zeiler\",\"@id\":\"\\\/#\\\/schema\\\/person\\\/92754ad381f49b3c358d1d8d2c4f90b8\"},\"headline\":\"\u00dcberraschende Wende: Biogen plant US-Zulassungsantrag f\u00fcr Alzheimer-Mittel\",\"datePublished\":\"2019-10-22T09:21:24+00:00\",\"dateModified\":\"2019-11-25T08:27:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\\\/\"},\"wordCount\":205,\"publisher\":{\"@id\":\"\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/digidem-bayern.de\\\/wp-content\\\/uploads\\\/2019\\\/10\\\/tabletten_pixabay2.jpg\",\"articleSection\":[\"Wissenschaft & Forschung\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\\\/\",\"url\":\"https:\\\/\\\/digidem-bayern.de\\\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\\\/\",\"name\":\"\u00dcberraschende Wende: Biogen plant US-Zulassungsantrag f\u00fcr Alzheimer-Mittel - digiDEM Bayern\",\"isPartOf\":{\"@id\":\"\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/digidem-bayern.de\\\/wp-content\\\/uploads\\\/2019\\\/10\\\/tabletten_pixabay2.jpg\",\"datePublished\":\"2019-10-22T09:21:24+00:00\",\"dateModified\":\"2019-11-25T08:27:18+00:00\",\"description\":\"Iim Fr\u00fchjahr stoppte der US-Biotechkonzern Biogen zwei gro\u00dfe Studien mit dem Alzheimer-Mittel Aducanumab. Doch nun setzt der Konzern erneut auf auf den Wirkstoff und plant sogar die US-Zulassung.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/digidem-bayern.de\\\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\\\/#primaryimage\",\"url\":\"https:\\\/\\\/digidem-bayern.de\\\/wp-content\\\/uploads\\\/2019\\\/10\\\/tabletten_pixabay2.jpg\",\"contentUrl\":\"https:\\\/\\\/digidem-bayern.de\\\/wp-content\\\/uploads\\\/2019\\\/10\\\/tabletten_pixabay2.jpg\",\"width\":1600,\"height\":1067,\"caption\":\"Tabletten\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/digidem-bayern.de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00dcberraschende Wende: Biogen plant US-Zulassungsantrag f\u00fcr Alzheimer-Mittel\"}]},{\"@type\":\"WebSite\",\"@id\":\"\\\/#website\",\"url\":\"\\\/\",\"name\":\"digiDEM Bayern\",\"description\":\"Das digitale Demenzregister Bayern erforscht und verbessert die Angebotsstuktur f\u00fcr Menschen mit Demenz und deren Angeh\u00f6rige\",\"publisher\":{\"@id\":\"\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\\\/#organization\",\"name\":\"digiDEM Bayern\",\"url\":\"\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/digidem-bayern.de\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/cropped-Allgemeines_digiDEMLOGO-removebg-preview.png\",\"contentUrl\":\"https:\\\/\\\/digidem-bayern.de\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/cropped-Allgemeines_digiDEMLOGO-removebg-preview.png\",\"width\":612,\"height\":357,\"caption\":\"digiDEM Bayern\"},\"image\":{\"@id\":\"\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/digiDEMBayern\\\/\",\"https:\\\/\\\/x.com\\\/digidem_bayern\",\"https:\\\/\\\/www.instagram.com\\\/digidem.bayern\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/digidem-bayern\\\/\"]},{\"@type\":\"Person\",\"@id\":\"\\\/#\\\/schema\\\/person\\\/92754ad381f49b3c358d1d8d2c4f90b8\",\"name\":\"Michael Zeiler\",\"url\":\"https:\\\/\\\/digidem-bayern.de\\\/en\\\/author\\\/michael-zeiler\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u00dcberraschende Wende: Biogen plant US-Zulassungsantrag f\u00fcr Alzheimer-Mittel - digiDEM Bayern","description":"Iim Fr\u00fchjahr stoppte der US-Biotechkonzern Biogen zwei gro\u00dfe Studien mit dem Alzheimer-Mittel Aducanumab. Doch nun setzt der Konzern erneut auf auf den Wirkstoff und plant sogar die US-Zulassung.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/digidem-bayern.de\/en\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\/","og_locale":"en_US","og_type":"article","og_title":"\u00dcberraschende Wende: Biogen plant US-Zulassungsantrag f\u00fcr Alzheimer-Mittel - digiDEM Bayern","og_description":"Iim Fr\u00fchjahr stoppte der US-Biotechkonzern Biogen zwei gro\u00dfe Studien mit dem Alzheimer-Mittel Aducanumab. Doch nun setzt der Konzern erneut auf auf den Wirkstoff und plant sogar die US-Zulassung.","og_url":"https:\/\/digidem-bayern.de\/en\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\/","og_site_name":"digiDEM Bayern","article_publisher":"https:\/\/www.facebook.com\/digiDEMBayern\/","article_published_time":"2019-10-22T09:21:24+00:00","article_modified_time":"2019-11-25T08:27:18+00:00","og_image":[{"width":1600,"height":1067,"url":"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg","type":"image\/jpeg"}],"author":"Michael Zeiler","twitter_misc":{"Written by":"Michael Zeiler","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/digidem-bayern.de\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\/#article","isPartOf":{"@id":"https:\/\/digidem-bayern.de\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\/"},"author":{"name":"Michael Zeiler","@id":"\/#\/schema\/person\/92754ad381f49b3c358d1d8d2c4f90b8"},"headline":"\u00dcberraschende Wende: Biogen plant US-Zulassungsantrag f\u00fcr Alzheimer-Mittel","datePublished":"2019-10-22T09:21:24+00:00","dateModified":"2019-11-25T08:27:18+00:00","mainEntityOfPage":{"@id":"https:\/\/digidem-bayern.de\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\/"},"wordCount":205,"publisher":{"@id":"\/#organization"},"image":{"@id":"https:\/\/digidem-bayern.de\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\/#primaryimage"},"thumbnailUrl":"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg","articleSection":["Wissenschaft & Forschung"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/digidem-bayern.de\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\/","url":"https:\/\/digidem-bayern.de\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\/","name":"\u00dcberraschende Wende: Biogen plant US-Zulassungsantrag f\u00fcr Alzheimer-Mittel - digiDEM Bayern","isPartOf":{"@id":"\/#website"},"primaryImageOfPage":{"@id":"https:\/\/digidem-bayern.de\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\/#primaryimage"},"image":{"@id":"https:\/\/digidem-bayern.de\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\/#primaryimage"},"thumbnailUrl":"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg","datePublished":"2019-10-22T09:21:24+00:00","dateModified":"2019-11-25T08:27:18+00:00","description":"Iim Fr\u00fchjahr stoppte der US-Biotechkonzern Biogen zwei gro\u00dfe Studien mit dem Alzheimer-Mittel Aducanumab. Doch nun setzt der Konzern erneut auf auf den Wirkstoff und plant sogar die US-Zulassung.","breadcrumb":{"@id":"https:\/\/digidem-bayern.de\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/digidem-bayern.de\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/digidem-bayern.de\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\/#primaryimage","url":"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg","contentUrl":"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg","width":1600,"height":1067,"caption":"Tabletten"},{"@type":"BreadcrumbList","@id":"https:\/\/digidem-bayern.de\/biogen-plant-us-zulassungsantrag-fuer-aducanumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/digidem-bayern.de\/"},{"@type":"ListItem","position":2,"name":"\u00dcberraschende Wende: Biogen plant US-Zulassungsantrag f\u00fcr Alzheimer-Mittel"}]},{"@type":"WebSite","@id":"\/#website","url":"\/","name":"digiDEM Bavaria","description":"The digital dementia register in Bavaria researches and improves the structure of services for people with dementia and their relatives","publisher":{"@id":"\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/#organization","name":"digiDEM Bavaria","url":"\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/#\/schema\/logo\/image\/","url":"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2022\/03\/cropped-Allgemeines_digiDEMLOGO-removebg-preview.png","contentUrl":"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2022\/03\/cropped-Allgemeines_digiDEMLOGO-removebg-preview.png","width":612,"height":357,"caption":"digiDEM Bayern"},"image":{"@id":"\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/digiDEMBayern\/","https:\/\/x.com\/digidem_bayern","https:\/\/www.instagram.com\/digidem.bayern","https:\/\/www.linkedin.com\/company\/digidem-bayern\/"]},{"@type":"Person","@id":"\/#\/schema\/person\/92754ad381f49b3c358d1d8d2c4f90b8","name":"Michael Zeiler","url":"https:\/\/digidem-bayern.de\/en\/author\/michael-zeiler\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",1600,1067,false],"thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-80x80.jpg",80,80,true],"medium":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-300x200.jpg",300,200,true],"medium_large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-768x512.jpg",768,512,true],"large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-1030x687.jpg",1030,687,true],"1536x1536":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",1536,1024,false],"2048x2048":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",1600,1067,false],"trp-custom-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",18,12,false],"qubely_landscape":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-1200x750.jpg",1200,750,true],"qubely_portrait":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-540x320.jpg",540,320,true],"qubely_thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-140x100.jpg",140,100,true],"post-thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-495x330.jpg",495,330,true],"kahuna-featured":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-495x350.jpg",495,350,true],"kahuna-featured-lp":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-690x350.jpg",520,264,true],"kahuna-featured-half":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-800x350.jpg",800,350,true],"kahuna-featured-third":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-512x350.jpg",512,350,true],"kahuna-lpbox-1":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-460x350.jpg",394,300,true],"kahuna-lpbox-2":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-460x350.jpg",460,350,true],"demand-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",36,24,false],"dddkt-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",36,24,false],"ddiqc-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",36,24,false],"ddtl-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2.jpg",36,24,false],"mailpoet_newsletter_max":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-1320x880.jpg",1320,880,true],"kahuna-lpbox-3":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-460x350.jpg",460,350,true],"kahuna-featured-square":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-512x512.jpg",512,512,true],"kahuna-featured-square-large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2019\/10\/tabletten_pixabay2-1024x1024.jpg",1024,1024,true]},"uagb_author_info":{"display_name":"Michael Zeiler","author_link":"https:\/\/digidem-bayern.de\/en\/author\/michael-zeiler\/"},"uagb_comment_info":0,"uagb_excerpt":"Neue Hoffnung f\u00fcr Alzheimer-Patienten? Erst im Fr\u00fchjahr stoppte der US-Biotechkonzern Biogen zwei gro\u00dfe Studien mit dem Alzheimer-Mittel Aducanumab, der Wirkstoff schien gescheitert. Doch nun gibt es eine Kehrtwende, der Konzern setzt erneut auf Aducanumab und plant sogar die US-Zulassung. Mittlerweile seien mehr Daten verf\u00fcgbar, eine neue Analyse habe ein positives …","_links":{"self":[{"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/posts\/3902","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/comments?post=3902"}],"version-history":[{"count":0,"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/posts\/3902\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/media\/3906"}],"wp:attachment":[{"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/media?parent=3902"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/categories?post=3902"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/tags?post=3902"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}